Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer

Comparison with PET and enhanced CT

Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Domeki, Yasushi Kaji, Satoru Morita, Narufumi Suganuma, Kazuro Sugimura

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with iodinated contrast agent and 18F-fluorodeoxyglucose (FDG) in the diagnosis of suspected uterine cancer recurrence and to assess the impact of PET/CT findings on clinical management, compared with PET alone and enhanced CT alone. Methods: Of 103 women who had undergone treatment for histopathologically proven uterine cervical or endometrial cancer, 90 underwent FDG-PET/contrast-enhanced CT examination for suspected recurrence. PET-alone, CT-alone, and fused PET/CT images were interpreted by two radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months. Differences among the three modalities were tested using the Cochran Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET alone were 79.5% (35/44), 73.9% (34/46), and 76.7% (69/90), respectively, whereas those of CT alone were 68.2% (30/44), 87.0% (40/46), and 77.8% (70/90), respectively, and those of PET/CT were 90.9% (40/44), 93.5% (43/46), and 92.2% (83/90), respectively. PET/CT findings resulted in a change of management in 38 of the 90 patients (42%) with an additional effect on patient management in 13 patients (14%) diagnosed by CT alone and 14 patients (16%) diagnosed by PET alone. Conclusion: FDG-PET/contrast-enhanced CT is a more accurate modality for assessing recurrence of uterine cancer, and led to more appropriate subsequent clinical management than that resulting from PET alone or enhanced CT alone.

Original languageEnglish
Pages (from-to)362-372
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume36
Issue number3
DOIs
Publication statusPublished - 2009 Mar
Externally publishedYes

Fingerprint

Uterine Neoplasms
Recurrence
Fluorodeoxyglucose F18
Endometrial Neoplasms
Uterine Cervical Neoplasms
Contrast Media
Positron Emission Tomography Computed Tomography
Sensitivity and Specificity

Keywords

  • FDG
  • PET/CT
  • Recurrence
  • Uterine cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer : Comparison with PET and enhanced CT. / Kitajima, Kazuhiro; Murakami, Koji; Yamasaki, Erena; Domeki, Yasushi; Kaji, Yasushi; Morita, Satoru; Suganuma, Narufumi; Sugimura, Kazuro.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, No. 3, 03.2009, p. 362-372.

Research output: Contribution to journalArticle

Kitajima, Kazuhiro ; Murakami, Koji ; Yamasaki, Erena ; Domeki, Yasushi ; Kaji, Yasushi ; Morita, Satoru ; Suganuma, Narufumi ; Sugimura, Kazuro. / Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer : Comparison with PET and enhanced CT. In: European Journal of Nuclear Medicine and Molecular Imaging. 2009 ; Vol. 36, No. 3. pp. 362-372.
@article{7351a2a3579a4366b7f8cb426fcd2172,
title = "Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: Comparison with PET and enhanced CT",
abstract = "Purpose: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with iodinated contrast agent and 18F-fluorodeoxyglucose (FDG) in the diagnosis of suspected uterine cancer recurrence and to assess the impact of PET/CT findings on clinical management, compared with PET alone and enhanced CT alone. Methods: Of 103 women who had undergone treatment for histopathologically proven uterine cervical or endometrial cancer, 90 underwent FDG-PET/contrast-enhanced CT examination for suspected recurrence. PET-alone, CT-alone, and fused PET/CT images were interpreted by two radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months. Differences among the three modalities were tested using the Cochran Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET alone were 79.5{\%} (35/44), 73.9{\%} (34/46), and 76.7{\%} (69/90), respectively, whereas those of CT alone were 68.2{\%} (30/44), 87.0{\%} (40/46), and 77.8{\%} (70/90), respectively, and those of PET/CT were 90.9{\%} (40/44), 93.5{\%} (43/46), and 92.2{\%} (83/90), respectively. PET/CT findings resulted in a change of management in 38 of the 90 patients (42{\%}) with an additional effect on patient management in 13 patients (14{\%}) diagnosed by CT alone and 14 patients (16{\%}) diagnosed by PET alone. Conclusion: FDG-PET/contrast-enhanced CT is a more accurate modality for assessing recurrence of uterine cancer, and led to more appropriate subsequent clinical management than that resulting from PET alone or enhanced CT alone.",
keywords = "FDG, PET/CT, Recurrence, Uterine cancer",
author = "Kazuhiro Kitajima and Koji Murakami and Erena Yamasaki and Yasushi Domeki and Yasushi Kaji and Satoru Morita and Narufumi Suganuma and Kazuro Sugimura",
year = "2009",
month = "3",
doi = "10.1007/s00259-008-0956-1",
language = "English",
volume = "36",
pages = "362--372",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer

T2 - Comparison with PET and enhanced CT

AU - Kitajima, Kazuhiro

AU - Murakami, Koji

AU - Yamasaki, Erena

AU - Domeki, Yasushi

AU - Kaji, Yasushi

AU - Morita, Satoru

AU - Suganuma, Narufumi

AU - Sugimura, Kazuro

PY - 2009/3

Y1 - 2009/3

N2 - Purpose: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with iodinated contrast agent and 18F-fluorodeoxyglucose (FDG) in the diagnosis of suspected uterine cancer recurrence and to assess the impact of PET/CT findings on clinical management, compared with PET alone and enhanced CT alone. Methods: Of 103 women who had undergone treatment for histopathologically proven uterine cervical or endometrial cancer, 90 underwent FDG-PET/contrast-enhanced CT examination for suspected recurrence. PET-alone, CT-alone, and fused PET/CT images were interpreted by two radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months. Differences among the three modalities were tested using the Cochran Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET alone were 79.5% (35/44), 73.9% (34/46), and 76.7% (69/90), respectively, whereas those of CT alone were 68.2% (30/44), 87.0% (40/46), and 77.8% (70/90), respectively, and those of PET/CT were 90.9% (40/44), 93.5% (43/46), and 92.2% (83/90), respectively. PET/CT findings resulted in a change of management in 38 of the 90 patients (42%) with an additional effect on patient management in 13 patients (14%) diagnosed by CT alone and 14 patients (16%) diagnosed by PET alone. Conclusion: FDG-PET/contrast-enhanced CT is a more accurate modality for assessing recurrence of uterine cancer, and led to more appropriate subsequent clinical management than that resulting from PET alone or enhanced CT alone.

AB - Purpose: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) with iodinated contrast agent and 18F-fluorodeoxyglucose (FDG) in the diagnosis of suspected uterine cancer recurrence and to assess the impact of PET/CT findings on clinical management, compared with PET alone and enhanced CT alone. Methods: Of 103 women who had undergone treatment for histopathologically proven uterine cervical or endometrial cancer, 90 underwent FDG-PET/contrast-enhanced CT examination for suspected recurrence. PET-alone, CT-alone, and fused PET/CT images were interpreted by two radiologists by consensus for each investigation. Lesion status was determined on the basis of histopathology, radiological imaging and clinical follow-up for longer than 6 months. Differences among the three modalities were tested using the Cochran Q test, followed by multiple comparisons using the McNemar test with Bonferroni adjustment. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET alone were 79.5% (35/44), 73.9% (34/46), and 76.7% (69/90), respectively, whereas those of CT alone were 68.2% (30/44), 87.0% (40/46), and 77.8% (70/90), respectively, and those of PET/CT were 90.9% (40/44), 93.5% (43/46), and 92.2% (83/90), respectively. PET/CT findings resulted in a change of management in 38 of the 90 patients (42%) with an additional effect on patient management in 13 patients (14%) diagnosed by CT alone and 14 patients (16%) diagnosed by PET alone. Conclusion: FDG-PET/contrast-enhanced CT is a more accurate modality for assessing recurrence of uterine cancer, and led to more appropriate subsequent clinical management than that resulting from PET alone or enhanced CT alone.

KW - FDG

KW - PET/CT

KW - Recurrence

KW - Uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=60549110475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60549110475&partnerID=8YFLogxK

U2 - 10.1007/s00259-008-0956-1

DO - 10.1007/s00259-008-0956-1

M3 - Article

VL - 36

SP - 362

EP - 372

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 3

ER -